Search


 
 
Blog : Displaying 987-990 of 1169


The New Republic Asks Whether Baseball is Already Losing the Next Doping Battle

Posted by Osagie Obasogie on January 29th, 2008


Senator George Mitchell's 20 month investigation and subsequent report on the use of steroids, HGH, and other performance enhancers in baseball has rocked the sport to its knees. The proverbial asterisks no longer belongs solely to Barry Bonds, as fan favorites such as Miguel Tejada and Roger Clemens are also on the long list of players who are suspected of cheating their way to the top. But the folks over at The New Republic blog have shifted the focus of baseball's scrutiny from past to future by asking whether the sport is already losing the next big doping battle. In addition to the medical exemption loophole and the growth of HGH use in the absence of any tests to detect it, TNR takes a good look at gene doping, noting

This is the most speculative, but far-reaching, cheating strategy on the horizon: the possibility of using gene therapy to improve athletic performance. It's certainly unrealistic to expect baseball to have any well-defined strategy yet for dealin­g with it, but when Rep. Mark Souder (R-Ind.) asked [Major League Baseball Commissioner Bud] Selig about it, Selig seemed not to understand what Souder was talking about. He asked Souder to repeat the question three times, and then gave a brief, generic answer about baseball having hired the best anti-doping doctors in the country. This doesn't inspire much confidence that baseball will be ahead of the curve.





Synbio researcher: Synthetic human genome could be used in cloning by 2014

Posted by Marcy Darnovsky on January 24th, 2008


Dozens of news articles (1, 2, 3, 4) are reporting on today's publication in Science of another step toward the creation of artificial life.

According to Wired News, J. Craig Venter, president of the J. Craig Venter Institute where scientists performed the study, said in a teleconference today, "We consider this the second in our three-step process to create the first synthetic organism…What remains now that we have this complete synthetic chromosome…is to boot this up in a cell."

Also reported by Wired are remarks by synthetic biologist Christopher Voigt, who explains that plans call for researchers to "scale up from the simplest organisms to the most complex: human beings." Voigt estimates "that a synthetic human genome - which could be used in human cloning research - could be created by 2014."

In response, the ETC Group renewed its call for a moratorium on the release and commercialization of synthetic organisms. From its press statement:

Venter is claiming bragging rights to the world's longest length of synthetic DNA, but size isn't everything. The important question is not 'how long?' but 'how wise?'

While synthetic biology is speeding ahead in the lab and in the marketplace, societal debate and regulatory oversight is stalled and there has been no meaningful or inclusive discussion on how to govern synthetic biology in a safe and just way. In the absence of democratic oversight profiteering industrialists are tinkering with the building blocks of life for their own private gain. We regard that as unacceptable.





Financial analysts' advice on California stem cell research

Posted by Marcy Darnovsky on January 24th, 2008


Citing the Golden State's $14-billion budget shortfall, an editorial in Investor's Business Daily invites Californians to "revisit their decision to borrow $3 billion for a research effort driven more by politics than science" and to "save themselves a good deal of money by winding the program down."

Yes, the financial pundits are talking about Proposition 71, the 2004 stem cell research initiative. They quote Biopolitical Times blogger and CGS stem cell policy expert Jesse Reynolds, who "says he doubts if Proposition 71 would pass if it were on the ballot today." The editorial continues:

The proposition succeeded, Reynolds says, "because of the political shine of embryonic stem cell research . . . It was like a magic bullet aimed at Washington."





700 and Counting

Posted by Osagie Obasogie on January 22nd, 2008


Over the holiday season, in between re-runs of A Charlie Brown Christmas and minute-by-minute updates on where to find a Nintendo Wii, Big Pharma gave the Black community an odd stocking stuffer that received surprisingly little attention: a report by the pharmaceutical industry's lobbying and trade organization (PhRMA) noting that nearly 700 medications are in clinical development to treat diseases that disproportionately affect African-Americans.

It's important to point out that these medicines are not necessarily slated to become the next BiDil, i.e. drugs bearing a race specific label to suggest that they are somehow genetically tailored for only one group. Many of the drugs on PhRMA's list may benefit broader classes of patients beyond those who are Black.

But, given that the story behind BiDil's FDA approval represents how companies can push a failed drug through FDA approval using a questionable clinical trial design and the even more questionable theory that genes are largely responsible for racial disparities, PhRMA's approach should give us some pause. Someone more cynical than I might think that PhRMA is using this report to lay the foundation for race specificity to become the fallback plan whenever a drug's FDA approval for the general population falters.

The economics of this approach might make sense at first as it might help companies recoup the millions of dollars lost when a drug fails to reach market. But FDA approval of race-specific medicines doesn't always mean that communities of color are interested in taking them. Just ask any of the 70 staff members recently laid off from NitroMed after the company decided that BiDil's sales are so slow that it's no longer worth marketing the drug.





Displaying 987-990 of 1169  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 

 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications | about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 USA • • (p) 1.510.625.0819 • (F) 1.510.665.8760